The study investigates whether patients treated for neovascular (wet) age-related macular
degeneration (AMD), with intravitreal injection with bevacizumab (Avastin) after two years
need more injections with retained therapy response compared to patients being treated with
intravitreal injection with aflibercept (Eylea).
The study also aims to evaluate if there is a difference in best-corrected visual acuity,
macular thickness, recurrence interval, durability, cost efficiency, as well as
vision-related quality of life.